Skip to main content
SOMNOMED LIMITED logo

SOMNOMED LIMITED — Investor Relations & Filings

Ticker · SOM ISIN · AU000000SOM1 LEI · 529900NFR8QFOLJGP577 ASX Manufacturing
Open in API
Filings indexed 982 across all filing types
Latest filing 2024-04-15 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SOM

About SOMNOMED LIMITED

https://somnomed.com

SomnoMed Limited specializes in the development and manufacture of diagnostic and treatment solutions for sleep-related breathing disorders, primarily obstructive sleep apnea (OSA). The company is recognized for its Continuous Open Airway Therapy (COAT), which utilizes custom-fitted oral appliances to maintain an open airway during sleep. Its flagship product line, SomnoDent, offers a range of mandibular advancement devices designed to improve patient compliance and comfort compared to traditional continuous positive airway pressure (CPAP) therapy. SomnoMed focuses on clinical research and technological innovation to provide effective, non-invasive alternatives for patients suffering from mild to moderate OSA and snoring. The company serves a global market, collaborating with sleep dentists and physicians to deliver personalized treatment options that enhance long-term health outcomes and quality of life for individuals with sleep-disordered breathing.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - SOM 6 pages 18.3KB
Share Issue/Capital Change Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the number and type of securities to be quoted, issue dates, and related information about the securities issued as part of a previously announced transaction. This type of document is a formal announcement related to capital changes, specifically the quotation of new securities following a share issue. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital structure changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely a brief announcement but a detailed application form for quotation of securities.
2024-04-15 English
Completion of institutional component of Entitlement Offer 3 pages 229.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 10 April 2024 from SomnoMed Limited regarding the successful completion of the institutional component of an entitlement offer, which is a type of capital raising activity. It details the number of shares issued, the issue price, the use of proceeds, and the timetable for the retail component of the entitlement offer. The content focuses on fundraising and share issuance, with no financial statements or detailed financial performance data included. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other filing types. The document length is 7444 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion. Therefore, the correct classification is Capital/Financing Update (CAP).
2024-04-09 English
Reinstatement to Quotation 1 page 418.8KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX Compliance regarding the reinstatement to quotation of SomnoMed Limited's securities. It references a prior announcement about a trading update and changes to earnings guidance but does not contain any financial statements or detailed report content itself. The document is short (816 characters) and serves as a regulatory announcement rather than a full financial report or detailed update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements that do not fit other specific categories.
2024-04-09 English
Revised guidance and capital raising 6 pages 293.0KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from SomnoMed Limited regarding a revised FY24 financial guidance and a capital raising through an entitlement offer. It includes specific financial guidance updates, operational issues affecting manufacturing capacity, and detailed terms of the capital raising including the offer price, underwriting, and use of proceeds. The document focuses on financing activities and capital structure changes rather than presenting full financial statements or comprehensive annual or interim reports. It is not a full annual or interim report, nor is it a regulatory filing or a report publication announcement. The primary content is about the capital raising and related financial updates, which fits the definition of a Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2024-04-08 English
Prospectus Entitlement Offer 69 pages 1.1MB
Capital/Financing Update Classification · 100% confidence The document is titled 'Prospectus' and relates to a pro-rata accelerated non-renounceable entitlement offer to shareholders, including details about the offer, underwriting, legal notices, and international offer restrictions. It is a formal offer document prepared under section 713 of the Corporations Act, intended to raise capital by issuing new shares. The content focuses on the terms and conditions of the share offer, instructions for shareholders, and regulatory compliance for the offer. This type of document is a capital raising announcement and offer document, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full prospectus, not just an announcement of a report publication or a brief notice.
2024-04-08 English
Investor Presentation 16 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation' dated April 2024 and contains detailed sections including business updates, strategic plans, capital raising details, and financial outlook. It discusses operational challenges, manufacturing capacity issues, cost efficiency, revenue growth, and a capital raise of $22.6 million. The content is structured as a presentation with slides and investment highlights, focusing on the company's strategy, market opportunity, and use of funds. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The detailed nature and format align with an Investor Presentation (IP).
2024-04-08 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.